{"transactions":[{"id":830972,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.596,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":41665},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":830971,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":41665,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested."}],"balance_after":41665,"derivative":{"exercise_price":3.91,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":41665},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":830970,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.29,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":57950},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":830969,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":57950,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":57950,"derivative":{"exercise_price":3.91,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":57950},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":830968,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":830967,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:16:39.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":66000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":66000,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-120235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120235/ownership.xml","form_type":"4"}},{"id":888262,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-23T21:35:02.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":77000,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001193125-26-064141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064141/ownership.xml","form_type":"4"}},{"id":888261,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:35:02.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025."}],"balance_after":118823,"source":{"system":"sec-edgar","filing":"0001193125-26-064141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064141/ownership.xml","form_type":"4"}},{"id":944734,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-01-08T01:13:25.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":5956,"price":1.012,"value":6027.472,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025."}],"balance_after":75823,"source":{"system":"sec-edgar","filing":"0001193125-26-006765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526006765/ownership.xml","form_type":"4"}},{"id":944733,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-01-08T01:13:25.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3295,"price":1.003,"value":3304.885,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025."}],"balance_after":81779,"source":{"system":"sec-edgar","filing":"0001193125-26-006765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526006765/ownership.xml","form_type":"4"}},{"id":1238757,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-28T21:27:15.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":100500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."}],"balance_after":100500,"derivative":{"exercise_price":1.13,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":100500},"source":{"system":"sec-edgar","filing":"0000950170-25-030057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025030057/ownership.xml","form_type":"4"}},{"id":1238756,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-02-28T21:27:15.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":50250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":80074,"source":{"system":"sec-edgar","filing":"0000950170-25-030057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025030057/ownership.xml","form_type":"4"}},{"id":1308314,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-01-08T01:00:32.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":2957,"price":1.341,"value":3965.337,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,224 shares purchased on March 31, 2024 under the Issuer's Employee Stock Purchase Plan (\"ESPP\") and 2,322 shares purchased on September 30, 2024 under ESPP in transactions exempt from reporting under Section 16(b)3."}],"balance_after":29824,"source":{"system":"sec-edgar","filing":"0000950170-25-003157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025003157/ownership.xml","form_type":"4"}},{"id":1557656,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:16:55.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Previously reported on a Form 4 filed on March 18, 2024.  As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":28235,"source":{"system":"sec-edgar","filing":"0001610717-24-000192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000192/form4.xml","form_type":"4/A","original_submission_date":"2024-03-18"}},{"id":1572708,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-18T23:27:34.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":55000,"derivative":{"exercise_price":3,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001610717-24-000166","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000166/form4.xml","form_type":"4"}},{"id":1572707,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-18T23:27:34.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the adjusted total which includes the purchase of 735 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023."}],"balance_after":28235,"source":{"system":"sec-edgar","filing":"0001610717-24-000166","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000166/form4.xml","form_type":"4"}},{"id":2008109,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-18T00:28:17.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":57950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023."}],"balance_after":57950,"derivative":{"exercise_price":14.29,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":57950},"source":{"system":"sec-edgar","filing":"0000899243-23-005557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323005557/doc4.xml","form_type":"4"}},{"id":2270607,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56574,"kind":"person","name":"Chanda Sanjay","position":1,"cik":"0001571820","reported_name":"Chanda Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:32:40.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":66000,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0000899243-22-018296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018296/doc4.xml","form_type":"4"}}]}